In [177Lu]Lu-PSMA-617 therapy for metastasized prostate cancer, both the external dose rate of patients and the risk of radioactive contamination for caregivers and relatives are mainly determined by the urinary excretion of [177Lu]Lu-PSMA-617. Here, FOLH1 is linked to prostate cancer.